Meeting
Abstract Number: A8
SHM Converge 2022
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as the presence of ≥5% of hepatic steatosis (HS) in the absence of other liver disorders, such as chronic viral or autoimmune hepatitis, steatosis induced by drugs, significant alcohol consumption, hemochromatosis, or Wilson’s disease. There is limited literature describing national prevalence and epidemiological characteristics of NAFLD in […]
Abstract Number: L42
SHM Converge 2022
Case Presentation: A 19-year-old female presented with 1 month of worsening abdominal pain, 3 weeks of fevers / chills, 1 week of nausea/vomiting, and 4 days of rash. Her abdominal pain was intermittent, stabbing, diffuse, and worsening in severity. She also had daily chills and fevers (maximum temperature of 38.9 °C). Her emesis was non-bilious […]
Abstract Number: L46
SHM Converge 2022
Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]